67 Defining migraine days 3 symptoms such as nausea/vomiting or photophobia and phonophobia were present. Furthermore, 28.4% (n=4,268) of all days defined by triptan intake alone matched less than 2 migraine characteristics, and 5.3% (n=793) missed all three characteristics (Figure 1, overlapping part). Headache duration was the only missing criterion in 43.4% of days (Figure 1). Of these days, 97.7% still had a headache duration of ≥30 minutes. Adjusting the minimum headache duration to 30 minutes increased the total number of migraine days with 5.4% (n=5,720 days) to n=112,150 days compared to all baseline migraine days (Figure 2), which equaled a 0.45 day increase in MMD. In these additional migraine days introduced by a shortened duration criterion, an analgesic was used in 22.7% (data not shown). This percentage is comparable to the number of analgesic days in days defined by the baseline criteria (with a duration of ≥4 hours) (23.3%). Furthermore, these additional days had a median duration of 2.5 (IQR 2.0-3.0) hours, which is shown in Figure 3. Figure 1. Proportion of days based on migraine characteristics with a duration of ≥ 4 hours and/or triptan intake (irrespective of its effect). Percentages are calculated based on the total number of migraine days as defined by the baseline criteria for all patients in the dataset (n = 106,430 days). The righthand-side Venn diagrams show the missing migraine characteristics on days defined by triptan intake only.
RkJQdWJsaXNoZXIy MjY0ODMw